Inhibition of Ceramide Synthesis Reduces α-Synuclein Proteinopathy in a Cellular Model of Parkinson’s Disease
Authors:
- Alessandra MingioneAMAlessandra Mingione
- Francesca PivariFPFrancesca Pivari
- Nicoletta PlotegherNicoletta Plotegher
- Michele Dei CasMCMichele Dei Cas
- Aida ZuluetaAZAida Zulueta
- Tommaso BocciTBTommaso Bocci
- Marco TrincheraMarco Trinchera
- Elisabetta AlbiElisabetta Albi
- Vittorio MaglioneVMVittorio Maglione
- Anna CarettiACAnna Caretti
- Luigi BubaccoLBLuigi Bubacco
- Rita ParoniRita Paroni
Open Access
- 16 June 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (12) , 6469
Abstract
Parkinson’s disease (PD) is a proteinopathy associated with the aggregation of α-synuclein and the formation of lipid–protein cellular inclusions, named Lewy bodies (LBs). LB formation results in impaired neurotransmitter release and uptake, which involve membrane traffic and require lipid synthesis and metabolism. Lipids, particularly ceramides, are accumulated in postmortem PD brains and altered in the plasma of PD patients. Autophagy is impaired in PD, reducing the ability of neurons to clear protein aggregates, thus worsening stress conditions and inducing neuronal death. The inhibition of ceramide synthesis by myriocin (Myr) in SH-SY5Y neuronal cells treated with preformed α-synuclein fibrils reduced intracellular aggregates, favoring their sequestration into lysosomes. This was associated with TFEB activation, increased expression of TFEB and LAMP2, and the cytosolic accumulation of LC3II, indicating that Myr promotes autophagy. Myr significantly reduces the fibril-related production of inflammatory mediators and lipid peroxidation and activates NRF2, which is downregulated in PD. Finally, Myr enhances the expression of genes that control neurotransmitter transport (SNARE complex, VMAT2, and DAT), whose progressive deficiency occurs in PD neurodegeneration. The present study suggests that counteracting the accumulation of inflammatory lipids could represent a possible therapeutic strategy for PD.Keywords
Funding Information
- “Aldo Ravelli” Center for Neurotechnology and Experimental Brain Therapeutics, University of Milan, Milan, Italy. (CCE_FON16_CNBT_RAVELLI_PJ3)
This publication has 68 references indexed in Scilit:
- Plasma Ceramide and Glucosylceramide Metabolism Is Altered in Sporadic Parkinson's Disease and Associated with Cognitive Impairment: A Pilot StudyPLOS ONE, 2013
- Phenotypic Characterization of Retinoic Acid Differentiated SH-SY5Y Cells by Transcriptional ProfilingPLOS ONE, 2013
- It’s a Lipid’s World: Bioactive Lipid Metabolism and Signaling in Neural Stem Cell DifferentiationNeurochemical Research, 2012
- Lipid Pathway Alterations in Parkinson's Disease Primary Visual CortexPLOS ONE, 2011
- Inhibition of ceramide biosynthesis preserves photoreceptor structure and function in a mouse model of retinitis pigmentosaProceedings of the National Academy of Sciences, 2010
- Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's DiseaseNew England Journal of Medicine, 2009
- Emerging pathways in genetic Parkinson's disease: Potential role of ceramide metabolism in Lewy body diseaseThe FEBS Journal, 2008
- The Dystonia-associated Protein TorsinA Modulates Synaptic Vesicle RecyclingJournal of Biological Chemistry, 2008
- A guided tour into subcellular colocalization analysis in light microscopyJournal of Microscopy, 2006
- α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's ModelsScience, 2006